Amber Bio develops RNA editing medicines designed to rewrite thousands of bases at once, addressing diverse disease-causing mutations with a single therapy.
Products & media
USH2A program
Preclinical RNA editing program for USH2A correction, using Amber’s multi-kilobase RNA writing approach. Disclosed as the lead development program in the company’s BIO 2026 presentation.
Cosigns
Vineeta AgarwalaGeneral Partner at Andreessen Horowitz
“Jacob and Basem … have built a fast-moving, intensely creative, and yet product-focused team at Amber Bio”
“thrilled to support … the entire team at Amber Bio in pioneering new gene editing modalities using multi-kilobase RNA editing to treat undruggable diseases.”
Team
Founders
2 people
Jobs
See all jobs for Amber Bio here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
Seed
$26M